Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies
|
摘要
Hematopoietic stem cell transplant(HSCT) is a standard treatment for many hematological malignancies.Three different sources of stem cells, namely bone marrow(BM), peripheral blood stem cells(PBSC) and cord blood(CB) can be used for HSCT, and each has its own advantages and disadvantages. Randomized controlled trials(RCTs) suggest that there is no significant survival advantage of PBSC over BM in Human Leukocyte Antigen-matched sibling transplant for adult patients with hematological malignancies. PBSC transplant probably results in lower risk of relapse and hence better disease-free survival, especially in patients with high risk disease at the expense of higher risks of both severe acute and chronic graft-versus-host disease(GVHD).In the unrelated donor setting, the only RCT available suggests that PBSC and BM result in comparable overall and disease-free survivals in patients with hematological malignancies; and PBSC transplant results in lower risk of graft failure and higher risk of chronic GVHD.High level evidence is not available for CB in comparison to BM or PBSC. The risks and benefits of different sources of stem cells likely change with different conditioning regimen, strategies for prophylaxis and treatment of GVHD and manipulation of grafts. The recent success and rapid advance of double CB transplant and haploidentical BM and PBSC transplants further complicate the selection of stem cell source. Optimal selection requires careful weighing of the risks and benefits of different stem cell source for each individual recipient and donor. Detailed counseling of patient and donor regarding risks and benefits in the specific context of the patient and transplant method is essential for informed decision making.
Hematopoietic stem cell transplant(HSCT) is a standard treatment for many hematological malignancies.Three different sources of stem cells, namely bone marrow(BM), peripheral blood stem cells(PBSC) and cord blood(CB) can be used for HSCT, and each has its own advantages and disadvantages. Randomized controlled trials(RCTs) suggest that there is no significant survival advantage of PBSC over BM in Human Leukocyte Antigen-matched sibling transplant for adult patients with hematological malignancies. PBSC transplant probably results in lower risk of relapse and hence better disease-free survival, especially in patients with high risk disease at the expense of higher risks of both severe acute and chronic graft-versus-host disease(GVHD).In the unrelated donor setting, the only RCT available suggests that PBSC and BM result in comparable overall and disease-free survivals in patients with hematological malignancies; and PBSC transplant results in lower risk of graft failure and higher risk of chronic GVHD.High level evidence is not available for CB in comparison to BM or PBSC. The risks and benefits of different sources of stem cells likely change with different conditioning regimen, strategies for prophylaxis and treatment of GVHD and manipulation of grafts. The recent success and rapid advance of double CB transplant and haploidentical BM and PBSC transplants further complicate the selection of stem cell source. Optimal selection requires careful weighing of the risks and benefits of different stem cell source for each individual recipient and donor. Detailed counseling of patient and donor regarding risks and benefits in the specific context of the patient and transplant method is essential for informed decision making.
Hematopoietic stem cell transplant(HSCT) is a standard treatment for many hematological malignancies.Three different sources of stem cells, namely bone marrow(BM), peripheral blood stem cells(PBSC) and cord blood(CB) can be used for HSCT, and each has its own advantages and disadvantages. Randomized controlled trials(RCTs) suggest that there is no significant survival advantage of PBSC over BM in Human Leukocyte Antigen-matched sibling transplant for adult patients with hematological malignancies. PBSC transplant probably results in lower risk of relapse and hence better disease-free survival, especially in patients with high risk disease at the expense of higher risks of both severe acute and chronic graft-versus-host disease(GVHD).In the unrelated donor setting, the only RCT available suggests that PBSC and BM result in comparable overall and disease-free survivals in patients with hematological malignancies; and PBSC transplant results in lower risk of graft failure and higher risk of chronic GVHD.High level evidence is not available for CB in comparison to BM or PBSC. The risks and benefits of different sources of stem cells likely change with different conditioning regimen, strategies for prophylaxis and treatment of GVHD and manipulation of grafts. The recent success and rapid advance of double CB transplant and haploidentical BM and PBSC transplants further complicate the selection of stem cell source. Optimal selection requires careful weighing of the risks and benefits of different stem cell source for each individual recipient and donor. Detailed counseling of patient and donor regarding risks and benefits in the specific context of the patient and transplant method is essential for informed decision making.
引文
1 Gatti RA,Meuwissen HJ,Allen HD,Hong R,Good RA.Immunological reconstitution of sex-linked lymphopenic immunological deficiency.Lancet 1968;2:1366-1369[PMID:4177932 DOI:10.1016/S0140-6736(68)92673-1]
2 Krbling M,Freireich EJ.Twenty-five years of peripheral blood stem cell transplantation.Blood 2011;117:6411-6416[PMID:21460243 DOI:10.1182/blood-2010-12-322214]
3 Richman CM,Weiner RS,Yankee RA.Increase in circulating stem cells following chemotherapy in man.Blood 1976;47:1031-1039[PMID:1276467]
4 Socinski MA,Cannistra SA,Elias A,Antman KH,Schnipper L,Griffin JD.Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man.Lancet 1988;1:1194-1198[PMID:2897009 DOI:10.1016/S0140-6736(88)92012-0]
5 Dührsen U,Villeval JL,Boyd J,Kannourakis G,Morstyn G,Metcalf D.Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients.Blood 1988;72:2074-2081[PMID:3264199]
6 Prindull G,Prindull B,Meulen N.Haematopoietic stem cells(CFUc)in human cord blood.Acta Paediatr Scand 1978;67:413 -416[PMID:676726 DOI:10.1111/j.1651-2227.1978.tb16347.x]
7 Gluckman E,Broxmeyer HA,Auerbach AD,Friedman HS,Douglas GW,Devergie A,Esperou H,Thierry D,Socie G,Lehn P.Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling.N Engl J Med 1989;321:1174-1178[PMID:2571931 DOI:10.1056/NEJM198910263211707]
8 Switzer GE,Bruce JG,Harrington D,Haagenson M,Drex-ler R,Foley A,Confer D,Bishop M,Anderlini P,Rowley S,Leitman SF,Anasetti C,Wingard JR.Health-related quality of life of bone marrow versus peripheral bood stem cell donors:a prespecified subgroup analysis from a phase III RCTBMTCTN protocol 0201.Biol Blood Marrow Transplant 2013Nov 1;Epub ahead of print[PMID:24184336 DOI:10.1016/j.bbmt.2013.10.024]
9 Powles R,Mehta J,Kulkarni S,Treleaven J,Millar B,Marsden J,Shepherd V,Rowland A,Sirohi B,Tait D,Horton C,Long S,Singhal S.Allogeneic blood and bone-marrow stemcell transplantation in haematological malignant diseases:a randomised trial.Lancet 2000;355:1231-1237[PMID:10770306 DOI:10.1016/S0140-6736(00)02090-0]
10 Blaise D,Kuentz M,Fortanier C,Bourhis JH,Milpied N,Sutton L,Jouet JP,Attal M,Bordigoni P,Cahn JY,Boiron JM,Schuller MP,Moatti JP,Michallet M.Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia:a report from the SociétéFranaise de Greffe de Moelle.J Clin Oncol 2000;18:537-546[PMID:10653869]
11 Couban S,Simpson DR,Barnett MJ,Bredeson C,Hubesch L,Howson-Jan K,Shore TB,Walker IR,Browett P,Messner HA,Panzarella T,Lipton JH.A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies.Blood 2002;100:1525-1531[PMID:12176866DOI:10.1182/blood-2002-01-0048]
12 Bensinger WI,Martin PJ,Storer B,Clift R,Forman SJ,Negrin R,Kashyap A,Flowers ME,Lilleby K,Chauncey TR,Storb R,Appelbaum FR.Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.N Engl J Med 2001;344:175-181[PMID:11172139 DOI:10.1056/NEJM200101183440303]
13 Mielcarek M,Storer B,Martin PJ,Forman SJ,Negrin RS,Flowers ME,Inamoto Y,Chauncey TR,Storb R,Appelbaum FR,Bensinger WI.Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow.Blood 2012;119:2675-2678[PMID:22308289 DOI:10 .1182/blood-2011-12-396275]
14 Oehler VG,Radich JP,Storer B,Blume KG,Chauncey T,Clift R,Snyder DS,Forman SJ,Flowers ME,Martin P,Guthrie KA,Negrin RS,Appelbaum FR,Bensinger W.Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia.Biol Blood Marrow Transplant 2005;11:85 -92[PMID:15682068 DOI:10.1016/j.bbmt.2004.09.010]
15 Schmitz N,Bacigalupo A,Hasenclever D,Nagler A,Gluckman E,Clark P,Bourquelot P,Greinix H,Frickhofen N,Ringdén O,Zander A,Apperley JF,Gorin C,Borkett K,Schwab G,Goebel M,Russell NH,Gratwohl A.Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia:first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation.Bone Marrow Transplant 1998;21:995-1003[PMID:9632272]
16 Schmitz N,Beksac M,Hasenclever D,Bacigalupo A,Ruutu T,Nagler A,Gluckman E,Russell N,Apperley JF,Gorin NC,Szer J,Bradstock K,Buzyn A,Clark P,Borkett K,Gratwohl A.Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemi a.Blood 2002;100:761-767[PMID:12130483 DOI:10.1182/blood-2001-12-0304]
17 Schmitz N,Beksac M,Bacigalupo A,Ruutu T,Nagler A,Gluckman E,Russell N,Apperley J,Szerm J,Bradstock K,Buzyn A,Schlegelberger B,Matcham J,Gratwohl A.Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia:3-year results from the EBMT randomized trial.Haematologica 2005;90:643 -648[PMID:15921379]
18 Friedrichs B,Tichelli A,Bacigalupo A,Russell NH,Ruutu T,Shapira MY,Beksac M,Hasenclever D,SociéG,Schmitz N.Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow:a randomised trial.Lancet Oncol 2010;11:331-338[PMID:20117965 DOI:10 .1016/S1470-2045(09)70352-3]
19 Mohty M,Kuentz M,Michallet M,Bourhis JH,Milpied N,Sutton L,Jouet JP,Attal M,Bordigoni P,Cahn JY,Boiron JM,Blaise D.Chronic graft-versus-host disease after allogeneic blood stem cell transplantation:long-term results of a randomized study.Blood 2002;100:3128-3134[PMID:12384409DOI:10.1182/blood.V100.9.3128]
20 Flowers ME,Parker PM,Johnston LJ,Matos AV,Storer B,Bensinger WI,Storb R,Appelbaum FR,Forman SJ,Blume KG,Martin PJ.Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients:long-term followup of a randomized trial.Blood 2002;100:415-419[PMID:12091330 DOI:10.1182/blood-2002-01-0011]
21 Mahmoud H,Fahmy O,Kamel A,Kamel M,El-Haddad A,El-Kadi D.Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation.Bone Marrow Transplant 1999;24:355-358[PMID:10467322 DOI:10 .1038/sj.bmt.1701906]
22 Morton J,Hutchins C,Durrant S.Granulocyte-colonystimulating factor(G-CSF)-primed allogeneic bone marrow:significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells.Blood 2001;98:3186-3191[PMID:11719353]
23 Vigorito AC,Azevedo WM,Marques JF,Azevedo AM,Eid KA,Aranha FJ,Lorand-Metze I,Oliveira GB,Correa ME,Reis AR,Miranda EC,de Souza CA.A randomised,prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies.Bone Marrow Transplant 1998;22:1145-1151[PMID:9894716 DOI:10.1038/sj.bmt.1701510]
24 Cutler C,Giri S,Jeyapalan S,Paniagua D,Viswanathan A,Antin JH.Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation:a meta-analysis.J Clin Oncol 2001;19:3685-3691[PMID:11504750]
25 Heldal D,Tjnnfjord G,Brinch L,Albrechtsen D,Egeland T,Steen R,Solheim BG,Evensen SA.A randomised study of allogeneic transplantation with stem cells from blood or bone marrow.Bone Marrow Transplant 2000;25:1129-1136[PMID:10849524 DOI:10.1038/sj.bmt.1702422]
26 Horan JT,Liesveld JL,Fernandez ID,Lyman GH,Phillips GL,Lerner NB,Fisher SG.Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies:metaanalysis of randomized controlled trials.Bone Marrow Transplant 2003;32:293-298[PMID:12858201 DOI:10.1038/sj.bmt.1704112]
27 Stem Cell Trialists'Collaborative Group.Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies:an individual patient data meta-analysis of nine randomized trials.J Clin Oncol 2005;23:5074-5087[PMID:16051954 DOI:10 .1200/JCO.2005.09.020]
28 Pidala J,Anasetti C,Kharfan-Dabaja MA,Cutler C,Sheldon A,Djulbegovic B.Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation.Biol Blood Marrow Transplant 2009;15:1415-1421[PMID:19822301 DOI:10.1016/j.bbmt.2009.07.009]
29 Vigorito AC,Marques Júnior JF,Aranha FJ,Oliveira GB,Miranda EC,De Souza CA.A randomized,prospective comparison of allogeneic bone marrow and peripheralblood progenitor cell transplantation in the treatment of hematologic malignancies:an update.Haematologica 2001;86:665 -666[PMID:11418381]
30 Cornelissen JJ,van der Holt B,Petersen EJ,Vindelov L,Russel CA,Hglund M,Maertens J,Schouten HC,Braakman E,Steijaert MM,Zijlmans MJ,Slaper-Cortenbach I,Boogaerts MA,Lwenberg B,Verdonck LF.A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies.Exp Hematol 2003;31:855-864[PMID:14550800 DOI:10.1016/S0301-472 X(03)00195-4]
31 Chang YJ,Weng CL,Sun LX,Zhao YT.Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies:a meta-analysis based on time-to-event data from randomized controlled trials.Ann Hematol 2012;91:427-437[PMID:21789620 DOI:10.1007/s00277-011-1299-8]
32 Anasetti C,Logan BR,Lee SJ,Waller EK,Weisdorf DJ,Wingard JR,Cutler CS,Westervelt P,Woolfrey A,Couban S,Ehninger G,Johnston L,Maziarz RT,Pulsipher MA,Porter DL,Mineishi S,Mc Carty JM,Khan SP,Anderlini P,Bensinger WI,Leitman SF,Rowley SD,Bredeson C,Carter SL,Horowitz MM,Confer DL.Peripheral-blood stem cells versus bone marrow from unrelated donors.N Engl J Med 2012;367:1487-1496[PMID:23075175 DOI:10.1056/NEJMoa1203517]
33 Meisel R,Klingebiel T,Dilloo D.Peripheral blood stem cells versus bone marrow in pediatric unrelated donor stem cell transplantation.Blood 2013;121:863-865[PMID:23372155DOI:10.1182/blood-2012-12-469668]
34 Wang J,Zhan P,Ouyang J,Chen B,Zhou R,Yang Y.Unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients:A meta-analysis.Leuk Res 2010;34:1018-1022[PMID:20031212 DOI:10.1016/j.leukres.2009.11.020]
35 Rocha V,Cornish J,Sievers EL,Filipovich A,Locatelli F,Peters C,Remberger M,Michel G,Arcese W,Dallorso S,Tiedemann K,Busca A,Chan KW,Kato S,Ortega J,Vowels M,Zander A,Souillet G,Oakill A,Woolfrey A,Pay AL,Green A,Garnier F,Ionescu I,Wernet P,Sirchia G,Rubinstein P,Chevret S,Gluckman E.Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia.Blood 2001;97:2962-2971[PMID:11342418]
36 Barker JN,Davies SM,DeF or T,Ramsay NK,Weisdorf DJ,Wagner JE.Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow:results of a matched-pair analysis.Blood 2001;97:2957-2961[PMID:11342417]
37 Dalle JH,Duval M,Moghrabi A,Wagner E,Vachon MF,Barrette S,Bernstein M,Champagne J,David M,Demers J,Rousseau P,Winikoff R,Champagne MA.Results of an unrelated transplant search strategy using partially HLAmismatched cord blood as an immediate alternative to HLAmatched bone marrow.Bone Marrow Transplant 2004;33:605 -611[PMID:14743192 DOI:10.1038/sj.bmt.1704433]
38 Jacobsohn DA,Hewlett B,Ranalli M,Seshadri R,Duerst R,Kletzel M.Outcomes of unrelated cord blood transplants and allogeneic-related hematopoietic stem cell transplants in children with high-risk acute lymphocytic leukemia.Bone Marrow Transplant 2004;34:901-907[PMID:15361908 DOI:10 .1038/sj.bmt.1704681]
39 Laughlin MJ,Eapen M,Rubinstein P,Wagner JE,Zhang MJ,Champlin RE,Stevens C,Barker JN,Gale RP,Lazarus HM,Marks DI,van Rood JJ,Scaradavou A,Horowitz MM.Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia.N Engl J Med 2004;351:2265-2275[PMID:15564543 DOI:10.1056/NEJMoa041276]
40 Rocha V,Labopin M,Sanz G,Arcese W,Schwerdtfeger R,Bosi A,Jacobsen N,Ruutu T,de Lima M,Finke J,Frassoni F,Gluckman E.Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.N Engl J Med 2004;351:2276-2285[PMID:15564544DOI:10.1056/NEJMoa041469]
41 Takahashi S,Iseki T,Ooi J,Tomonari A,Takasugi K,Shimohakamada Y,Yamada T,Uchimaru K,Tojo A,Shirafuji N,Kodo H,Tani K,Takahashi T,Yamaguchi T,Asano S.Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies.Bloo d 2004;104:3813-3820[PMID:15280199 DOI:10.1182/blood-2004-03-1001]
42 Barker JN,Hough RE,van Burik JA,De For TE,MacM illan ML,O’Brien MR,Wagner JE.Serious infections after unrelated donor transplantation in 136 children:impact of stem cell source.Biol Blood Marrow Transplant 2005;11:362-370[PMID:15846290 DOI:10.1016/j.bbmt.2005.02.004]
43 Eapen M,Rubinstein P,Zhang MJ,Stevens C,Kurtzberg J,Scaradavou A,Loberiza FR,Champlin RE,Klein JP,Horowitz MM,Wagner JE.Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia:a comparison study.Lancet 2007;369:1947-1954[PMID:17560447 DOI:10.1016/S0140-6736(07)60915-5]
44 Atsuta Y,Suzuki R,Nagamura-Inoue T,Taniguchi S,Takahashi S,Kai S,Sakamaki H,Kouzai Y,Kasai M,Fukuda T,Azuma H,Takanashi M,Okamoto S,Tsuchida M,Kawa K,Morishima Y,Kodera Y,Kato S.Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia.Blood 2009;113:1631-1638[PMID:19104080DOI:10.1182/blood-2008-03-147041]
45 Eapen M,Rocha V,Sanz G,Scaradavou A,Zhang MJ,Arcese W,Sirvent A,Champlin RE,Chao N,Gee AP,Isola L,Laughlin MJ,Marks DI,Nabhan S,Ruggeri A,Soiffer R,Horowitz MM,Gluckman E,Wagner JE.Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia:a retrospective analysis.Lancet Oncol 2010;11:653-660[PMID:20558104DOI:10.1016/S1470-2045(10)70127-3]
46 Marks DI,Woo KA,Zhong X,Appelbaum FR,Bachanova V,Barker JN,Brunstein CG,Gibson J,Kebriaei P,Lazarus HM,Olsson R,Perales MA,Pidala J,Savani B,Rocha V,Eapen M.Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission:a comparison with allografts from adult unrelated donors.Haematologica 2013 Sep 20;Epub ahead of print[PMID:24056817 DOI:10.3324/haematol.2013.094193]
47 Mac Millan ML,Weisdorf DJ,Brunstein CG,Cao Q,De For TE,Verneris MR,Blazar BR,Wagner JE.Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation:analysis of risk factors.Bl ood 2009;113:2410-2415[PMID:18997171 DOI:10.1182/blood-2008-07-163238]
48 Brunstein CG,Barker JN,Weisdorf DJ,DeF or TE,Miller JS,Blazar BR,Mc Glave PB,Wagner JE.Umbilical cord blood transplantation after nonmyeloablative conditioning:impact on transplantation outcomes in 110 adults with hematologic disease.Blood 2007;110:3064-3070[PMID:17569820 DOI:10 .1182/blood-2007-04-067215]
49 Verneris MR,Brunstein CG,Barker J,MacM illan ML,DeF or T,Mc Kenna DH,Burke MJ,Blazar BR,Miller JS,Mc Glave PB,Weisdorf DJ,Wagner JE.Relapse risk after umbilical cord blood transplantation:enhanced graft-versus-leukemia effect in recipients of 2 units.Blood 2009;114:4293-4299[PMID:19706886 DOI:10.1182/blood-2009-05-220525]
50 Sideri A,Neokleous N,Brunet De La Grange P,Guerton B,Le Bousse Kerdilles MC,Uzan G,Peste-Tsilimidos C,Gluckman E.An overview of the progress on double umbilical cord blood transplantation.Haematologica 2011;96:1213-1220[PMID:21546497 DOI:10.3324/haematol.2010.038836]
51 Sanz J,Wagner JE,Sanz MA,Defor T,Montesinos P,Bachanova V,Lorenzo I,Warlick E,Sanz GF,Brunstein C.Myeloablative cord blood transplantation in adults with acute leukemia:comparison of two different transplant platforms.Biol Blood Marrow Transplant 2013;19:1725-1730[PMID:24090598 DOI:10.1016/j.bbmt.2013.09.015]
52 Ruggeri A,Sanz G,Bittencourt H,Sanz J,Rambaldi A,Volt F,Yakoub-Agha I,Ribera JM,Mannone L,Sierra J,Mohty M,Solano C,Nabhan S,Arcese W,Gluckman E,Labopin M,Rocha V.Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen,a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT.Leukemia 2013 Sep 5;Epub ahead of print[PMID:24005245 DOI:10.1038/leu.2013.259]
53 Kindwall-Keller TL,Hegerfeldt Y,Meyerson HJ,Margevicius S,Fu P,van Heeckeren W,Lazarus HM,Cooper BW,Gerson SL,Barr P,Tse WW,Curtis C,Fanning LR,Creger RJ,Carlson-Barko JM,Laughlin MJ.Prospective study of onevs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies.Bone Marrow Transplant 2012;47:924-933[PMID:22002488 DOI:10.1038/bmt.2011.195]
54 Rodrigues CA,Sanz G,Brunstein CG,Sanz J,Wagner JE,Renaud M,de Lima M,Cairo MS,Fürst S,Rio B,Dalley C,Carreras E,Harousseau JL,Mohty M,Taveira D,Dreger P,Sureda A,Gluckman E,Rocha V.Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies:a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation.J Clin Oncol 2009;27:256-263[PMID:19064984 DOI:10.1200/JCO.2007.15.8865]
55 Avery S,Barker JN.Cord blood transplants:one,two or more unitsCurr Opin Hematol 2010;17:531-537[PMID:20739881 DOI:10.1097/MOH.0b013e32833e5b59]
56 Scaradavou A,Brunstein CG,Eapen M,Le-Rademacher J,Barker JN,Chao N,Cutler C,Delaney C,Kan F,Isola L,Karanes C,Laughlin MJ,Wagner JE,Shpall EJ.Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia.Blood 2013;121:752-758[PMID:23223509 DOI:10.1182/blood-2012-08-449108]
57 Goldstein G,Elhasid R,Bielorai B,Shimoni A,Yerushalmi R,Kassis I,Nagler A.Adults requiring cord blood transplants but have insufficient cell doses from a single cord blood unit can receive two units with successful engraftment kinetics similar to those of children receiving a single unit.Leuk Lymphoma 2011;52:635-641[PMID:21338286 DOI:10.3109/10428194.2010.548109]
58 Yoo KH,Lee SH,Sung KW,Koo HH,Chung NG,Cho B,Kim HK,Kang HJ,Shin HY,Ahn HS,Baek HJ,Han DK,Kook H,Hwang TJ,Kim SY,Lee YH,Hah JO,Im HJ,Seo JJ,Park SK,Jung HJ,Park JE,Lim YJ,Park SS,Lim YT,Yoo ES,Ryu KH,Park HJ,Park BK.Current status of pediatric umbilical cord blood transplantation in Korea:a multicenter retrospective analysis of 236 cases.Am J Hematol 2011;86:12 -17[PMID:21064135 DOI:10.1002/ajh.21886]
59 Robin M,Sanz GF,Ionescu I,Rio B,Sirvent A,Renaud M,Carreras E,Milpied N,Mohty M,Beguin Y,Bordigoni P,de Witte T,Picardi A,Purtill D,Gluckman E,Kroger N,Rocha V.Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia:a survey on behalf of Eurocord and CLWP of EBMT.Leukemia 2011;25:75-81[PMID:20882048 DOI:10.1038/leu.2010.219]
60 Labopin M,Ruggeri A,Gorin NC,Gluckman E,Blaise D,Mannone L,Milpied N,Yakoub-Agha I,Deconinck E,Michallet M,Fegueux N,SociéG,Nguyen S,Cahn JY,de Revel T,Garnier F,Faucher C,Taright N,Kenzey C,Volt F,Bertrand D,Mohty M,Rocha V.Cost-effectiveness and clinical outcomes of double versus single cord bloodtransplantation in adults with acute leukemia in France.Haematologica 2013Oct 18;Epub ahead of print[PMID:24143000 DOI:10.3324/haematol.2013.092254]
61 Rocha V,Labopin M,Ruggeri A,PodestàM,Gallamini A,Bonifazi F,Sanchez-Guijo FM,Rovira M,Socie G,Baltadakis I,Michallet M,Deconinck E,Bacigalupo A,Mohty M,Gluckman E,Frassoni F.Unrelated cord blood transplantation:outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies.Transplantation 2013;95:1284-1291[PMID:23507699 DOI:10.1097/TP.0b013e318288ca4d]
62 Brunstein CG,Gutman JA,Weisdorf DJ,Woolfrey AE,Defor TE,Gooley TA,Verneris MR,Appelbaum FR,Wagner JE,Delaney C.Allogeneic hematopoietic cell transplantation for hematologic malignancy:relative risks and benefits of double umbilical cord blood.Blood 2010;116:4693-4699[PMID:20686119 DOI:10.1182/blood-2010-05-285304]
63 Ponce DM,Zheng J,Gonzales AM,Lubin M,Heller G,Castro-Malaspina H,Giralt S,Hsu K,Jakubowski AA,Jenq RR,Koehne G,Papadopoulos EB,Perales MA,van den Brink MR,Young JW,Boulad F,Kernan NA,Kobos R,Prockop S,Scaradavou A,Small T,O’Reilly RJ,Barker JN.Reduced late mortality risk contributes to similar survival after doubleunit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation.Biol Blood Marrow Transplant 2011;17:1316-1326[PMID:21232625DOI:10.1016/j.bbmt.2011.01.006]
64 Malard F,Fürst S,Loirat M,Chevallier P,El-Cheikh J,Guillaume T,Delaunay J,Le Gouill S,Moreau P,Blaise D,Mohty M.Effect of graft source on mismatched unrelated donor hemopoietic stem cell transplantation after reduced intensity conditioning.Leukemia 2013;27:2113-2117[PMID:23752174DOI:10.1038/leu.2013.170]
65 Le Bourgeois A,Mohr C,Guillaume T,Delaunay J,Malard F,Loirat M,Peterlin P,Blin N,Dubruille V,Mahe B,Gastinne T,Le Gouill S,Moreau P,Mohty M,Planche L,Lode L,Bene MC,Chevallier P.Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases:a single-center analysis.Biol Blood Marrow Transplant 2013;19:934-939[PMID:23523970 DOI:10.1016/j.bbmt.2013.03.009]
66 Chen YB,Aldridge J,Kim HT,Ballen KK,Cutler C,Kao G,Liney D,Bourdeau G,Alyea EP,Armand P,Koreth J,Ritz J,Spitzer TR,Soiffer RJ,Antin JH,Ho VT.Reduced-intensity conditioning stem cell transplantation:comparison of double umbilical cord blood and unrelated donor grafts.Biol Blood Marrow Transplant 2012;18:805-812[PMID:22015993 DOI:10 .1016/j.bbmt.2011.10.016]
67 Jacobson CA,Turki AT,Mc Donough SM,Stevenson KE,Kim HT,Kao G,Herrera MI,Reynolds CG,Alyea EP,Ho VT,Koreth J,Armand P,Chen YB,Ballen K,Soiffer RJ,Antin JH,Cutler CS,Ritz J.Immune reconstitution after double umbilical cord blood stem cell transplantation:comparison with unrelated peripheral blood stem cell transplantation.Biol Blood Marrow Transplant 2012;18:565-574[PMID:21875503DOI:10.1016/j.bbmt.2011.08.018]
68 Di Bartolomeo P,Santarone S,De Angelis G,Picardi A,Cudillo L,Cerretti R,Adorno G,Angelini S,Andreani M,De Felice L,Rapanotti MC,Sarmati L,Bavaro P,Papalinetti G,Di Nicola M,Papola F,Montanari M,Nagler A,Arcese W.Haploidentical,unmanipulated,G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies.Blood 2013;121:849-857[PMID:23165479 DOI:10 .1182/blood-2012-08-453399]
69 Aversa F,Terenzi A,Tabilio A,Falzetti F,Carotti A,Ballanti S,Felicini R,Falcinelli F,Velardi A,Ruggeri L,Aloisi T,Saab JP,Santucci A,Perruccio K,Martelli MP,Mecucci C,Reisner Y,Martelli MF.Full haplotype-mismatched hematopoietic stem-cell transplantation:a phase II study in patients with acute leukemia at high risk of relapse.J Clin Oncol 2005;23:3447-3454[PMID:15753458 DOI:10.1200/JCO.2005.09.117]
70 Ciurea SO,Saliba R,Rondon G,Pesoa S,Cano P,FernandezVina M,Qureshi S,Worth LL,Mc Mannis J,Kebriaei P,Jones RB,Korbling M,Qazilbash M,Shpall EJ,Giralt S,de Lima M,Champlin RE,Gajewski J.Reduced-intensity conditioning using fludarabine,melphalan and thiotepa for adult patients undergoing haploidentical SCT.Bone Marrow Transplant 2010;45:429-436[PMID:19668237 DOI:10.1038/bmt.2009.189]
71 Aversa F,Terenzi A,Felicini R,Tabilio A,Falzetti F,Carotti A,Falcinelli F,Sodani P,Amici A,Zucchetti P,Mazzarino I,Martelli MF.Mismatched T cell-depleted hematopoietic stem cell transplantation for children with high-risk acute leukemia.Bone Marrow Transplant 1998;22 Suppl 5:S29-S32[PMID:9989886]
72 Handgretinger R,Klingebiel T,Lang P,Schumm M,Neu S,Geiselhart A,Bader P,Schlegel PG,Greil J,Stachel D,Herzog RJ,Niethammer D.Megadose transplantation of purified peripheral blood CD34(+)progenitor cells from HLA-mismatched parental donors in children.Bone Marrow Transplant 2001;27:777-783[PMID:11477433 DOI:10.1038/sj.bmt.1702996]
73 Peters C,Matthes-Martin S,Fritsch G,Holter W,Lion T,Witt V,Hcker P,Fischer G,Dieckmann K,Handgretinger R,Klingebiel T,Gadner H.Transplantation of highly purified peripheral blood CD34+cells from HLA-mismatched parental donors in 14 children:evaluation of early monitoring of engraftment.Leukemia 1999;13:2070-2078[PMID:10602431]
74 Ortín M,Raj R,Kinning E,Williams M,Darbyshire PJ.Partially matched related donor peripheral blood progenitor cell transplantation in paediatric patients adding fludarabine and anti-lymphocyte gamma-globulin.Bone Marrow Transplant 2002;30:359-366[PMID:12235520 DOI:10.1038/sj.bmt.1703667]
75 Lang P,Greil J,Bader P,Handgretinger R,Klingebiel T,Schumm M,Schlegel PG,Feuchtinger T,Pfeiffer M,ScheelWalter H,Führer M,Martin D,Niethammer D.Long-term outcome after haploidentical stem cell transplantation in children.Blood Cells Mol Dis 2004;33:281-287[PMID:15528145 DOI:10.1016/j.bcmd.2004.08.017]
76 Klingebiel T,Handgretinger R,Lang P,Bader P,Niethammer D.Haploidentical transplantation for acute lymphoblastic leukemia in childhood.Blood Rev 2004;18:181-192[PMID:15183902 DOI:10.1016/S0268-960X(03)00063-8]
77 Marks DI,Khattry N,Cummins M,Goulden N,Green A,Harvey J,Hunt LP,Keen L,Robinson SP,Steward CG,Cornish JM.Haploidentical stem cell transplantation for children with acute leukaemia.Br J Haematol 2006;134:196-201[PMID:16846478 DOI:10.1111/j.1365-2141.2006.06140.x]
78 Reisner Y,Martelli MF.Tolerance induction by‘megadose’transplants of CD34+stem cells:a new option for leukemia patients without an HLA-matched donor.Curr Opin Immunol 2000;12:536-541[PMID:11007356]
79 Klingebiel T,Cornish J,Labopin M,Locatelli F,Darbyshire P,Handgretinger R,Balduzzi A,Owoc-Lempach J,Fagioli F,Or R,Peters C,Aversa F,Polge E,Dini G,Rocha V.Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia:impact of center size:an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group.Blood 2010;115:3437-3446[PMID:20040760 DOI:10.1182/blood-2009-03-207001]
80 Symons HJ,Leffell MS,Rossiter ND,Zahurak M,Jones RJ,Fuchs EJ.Improved survival with inhibitory killer immunoglobulin receptor(KIR)gene mismatches and KIR haplotype B donors after nonmyeloablative,HLA-haploidentical bone marrow transplantation.Biol Blood Marrow Transplant 2010;16:533-542[PMID:19961944 DOI:10.1016/j.bbmt.2009.11.022]
81 Lang P,Schumm M,Greil J,Bader P,Klingebiel T,Müller I,Feuchtinger T,Pfeiffer M,Schlegel PG,Niethammer D,Handgretinger R.A comparison between three graft manipulation methods for haploidentical stem cell transplantation in pediatric patients:preliminary results of a pilot study.Klin Padiatr 2005;217:334-338[PMID:16307419 DOI:10.1055/s-2005-872529]
82 Federmann B,Bornhauser M,Meisner C,Kordelas L,Beelen DW,Stuhler G,Stelljes M,Schwerdtfeger R,Christopeit M,Behre G,Faul C,Vogel W,Schumm M,Handgretinger R,Kanz L,Bethge WA.Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning:a phase II study.Haematologica 2012;97:1523-1531[PMID:22491731 DOI:10.3324/haematol.2011.059378]
83 Palma J,Salas L,Carrión F,Sotomayor C,Catalán P,Paris C,Turner V,Jorquera H,Handgretinger R,Rivera GK.Haploidentical stem cell transplantation for children with highrisk leukemia.Pediatr Blood Cancer 2012;59:895-901[PMID:22238059 DOI:10.1002/pbc.24022]
84 Chen DF,Prasad VK,Broadwater G,Reinsmoen NL,DeOliveira A,Clark A,Sullivan KM,Chute JP,Horwitz ME,Gasparetto C,Long GD,Yang Y,Chao NJ,Rizzieri DA.Differential impact of inhibitory and activating Killer Ig-Like Receptors(KIR)on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors.Bone Marrow Transplant 2012;47:817-823[PMID:22139069 DOI:10.1038/bmt.2011.181]
85 Handgretinger R,Chen X,Pfeiffer M,Mueller I,Feuchtinger T,Hale GA,Lang P.Feasibility and outcome of reducedintensity conditioning in haploidentical transplantation.Ann N Y Acad Sci 2007;1106:279-289[PMID:17442774 DOI:10 .1196/annals.1392.022]
86 Chen X,Hale GA,Barfield R,Benaim E,Leung WH,Knowles J,Horwitz EM,Woodard P,Kasow K,Yusuf U,Behm FG,Hayden RT,Shurtleff SA,Turner V,Srivastava DK,Handgretinger R.Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies.Br J Haematol 2006;135:524-532[PMID:17010105 DOI:10.1111/j.1365-2141.2006.06330.x]
87 Raiola AM,Dominietto A,Ghiso A,Di Grazia C,Lamparelli T,Gualandi F,Bregante S,Van Lint MT,Geroldi S,Luchetti S,Ballerini F,Miglino M,Varaldo R,Bacigalupo A.Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.Biol Blood Marrow Transplant 2013;19:117-122[PMID:22940057 DOI:10 .1016/j.bbmt.2012.08.014]
88 Solomon SR,Sizemore CA,Sanacore M,Zhang X,Brown S,Holland HK,Morris LE,Bashey A.Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival:results of a prospective phase II trial.Biol Blood Marrow Transplant 2012;18:1859-1866[PMID:22863841 DOI:10 .1016/j.bbmt.2012.06.019]
89 Wang HX,Yan HM,Wang ZD,Xue M,Liu J,Guo ZK.Haploidentical hematopoietic stem cell transplantation in hematologic malignancies with G-CSF mobilized bone marrow plus peripheral blood stem cells grafts without T celldepletion:a single center report of 29 cases.Leuk Lymphoma 2012;53:654-659[PMID:21929286 DOI:10.3109/10428194.2011.624225]
90 Munchel AT,Kasamon YL,Fuchs EJ.Treatment of hematological malignancies with nonmyeloablative,HLAhaploidentical bone marrow transplantation and high dose,post-transplantation cyclophosphamide.Best Pract Res Clin Haematol 2011;24:359-368[PMID:21925089 DOI:10.1016/j.beha.2011.05.001]
91 Chen Y,Liu K,Xu L,Chen H,Liu D,Zhang X,Shi H,Han W,Wang Y,Zhao T,Wang J,Wang J,Huang X.HLAmismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome.Bone Marrow Transplant 2010;45:1333-1339[PMID:20062100 DOI:10.1038/bmt.2009.351]
92 Wang HX,Yan HM,Duan LN,Wang ZD,Zhu L,Xue M,Liu J,Hu LD,Guo ZK.Haploidentical hematopoietic stem cell transplantation in child hematologic malignancies with G-CSF-mobilized marrow grafts without T-cell depletion:a single-center report of 45 cases.Pediatr Hematol Oncol 2009;26:119-128[PMID:19382033]
93 Luznik L,O’Donnell PV,Symons HJ,Chen AR,Leffell MS,Zahurak M,Gooley TA,Piantadosi S,Kaup M,Ambinder RF,Huff CA,Matsui W,Bolaos-Meade J,Borrello I,Powell JD,Harrington E,Warnock S,Flowers M,Brodsky RA,Sandmaier BM,Storb RF,Jones RJ,Fuchs EJ.HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose,posttransplantation cyclophosphamide.Biol Blood Marrow Transplant 2008;14:641-650[PMID:18489989 DOI:10.1016/j.bbmt.2008.03.005]
94 Liu D,Huang X,Liu K,Xu L,Chen H,Han W,Chen Y,Zhang X,Jiang Q.Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children.Biol Blood Marrow Transplant 2008;14:469-477[PMID:18342790 DOI:10 .1016/j.bbmt.2008.02.007]
95 Yoshihara T,Okada K,Kobayashi M,Kikuta A,Kato K,Adachi N,Kikuchi A,Ishida H,Hirota Y,Kuroda H,Nagatoshi Y,Inukai T,Koike K,Kigasawa H,Yagasaki H,Tokuda K,Kishimoto T,Nakano T,Fujita N,Goto H,Nakazawa Y,Kanegane H,Matsuzaki A,Osugi Y,Hasegawa D,Uoshima N,Nakamura K,Tsuchida M,Tanaka R,Watanabe A,Yabe H.Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents.Int J Hematol 2007;85:246-255[PMID:17483063 DOI:10.1532/IJH97.06185]
96 Bashey A,Zhang X,Sizemore CA,Manion K,Brown S,Holland HK,Morris LE,Solomon SR.T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.J Clin Oncol 2013;31:1310-1316[PMID:23423745 DOI:10 .1200/JCO.2012.44.3523]
97 Ciurea SO,Mulanovich V,Saliba RM,Bayraktar UD,Jiang Y,Bassett R,Wang SA,Konopleva M,Fernandez-Vina M,Montes N,Bosque D,Chen J,Rondon G,Alatrash G,Alousi A,Bashir Q,Korbling M,Qazilbash M,Parmar S,Shpall E,Nieto Y,Hosing C,Kebriaei P,Khouri I,Popat U,de Lima M,Champlin RE.Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.Biol Blood Marrow Transplant 2012;18:1835-1844[PMID:22796535 DOI:10 .1016/j.bbmt.2012.07.003]
98 Dodero A,Carniti C,Raganato A,Vendramin A,Farina L,Spina F,Carlo-Stella C,Di Terlizzi S,Milanesi M,Longoni P,Gandola L,Lombardo C,Corradini P.Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies:posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery.Blood 2009;113:4771-4779[PMID:19211934 DOI:10.1182/blood-2008-10-183723]
99 Di Ianni M,Falzetti F,Carotti A,Terenzi A,Castellino F,Bonifacio E,Del Papa B,Zei T,Ostini RI,Cecchini D,Aloisi T,Perruccio K,Ruggeri L,Balucani C,Pierini A,Sportoletti P,Aristei C,Falini B,Reisner Y,Velardi A,Aversa F,Martelli MF.Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation.Bl ood 2011;117:3921-3928[PMID:21292771 DOI:10.1182/blood-2010-10-311894]
100 Di Ianni M,Falzetti F,Carotti A,Terenzi A,Del Papa B,Perruccio K,Ruggeri L,Sportoletti P,Rosati E,Marconi P,Falini B,Reisner Y,Velardi A,Aversa F,Martelli MF.Immunoselection and clinical use of T regulatory cells in HLAhaploidentical stem cell transplantation.Best Pract Res Clin Haematol 2011;24:459-466[PMID:21925099 DOI:10.1016/j.beha.2011.05.005]
101 Liu K,Chen Y,Zeng Y,Xu L,Liu D,Chen H,Zhang X,Han W,Wang Y,Zhao T,Wang J,Wang J,Han Q,Zhao C,Huang X.Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation:a randomized,controlled clinical study.Stem Cells Dev 2011;20:1679-1685[PMID:21142788 DOI:10.1089/scd.2010.0447]
102 Ball LM,Bernardo ME,Roelofs H,Lankester A,Cometa A,Egeler RM,Locatelli F,Fibbe WE.Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation.Blood 2007;110:2764-2767[PMID:17638847 DOI:10.1182/blood-2007-04-087056]
103 Xu LP,Liu KY,Liu DH,Chen H,Han W,Chen YH,Wang Y,Huang XJ.The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation:a comparative analysis.Bone Marrow Transplant 2010;45:985-992[PMID:19898505 DOI:10.1038/bmt.2009.311]
104 Yan HM,Xue M,Wang ZD,Zhu L,Liu J,Ding L,Pan SP,Duan LN,Wang HX.[Haploidentical allogeneic bone marrow stem cell transplantation combined with peripheral blood stem cells for therapy of leukemia].Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009;17:1330-1334[PMID:19840477]
105 Vago L,Oliveira G,Bondanza A,Noviello M,Soldati C,Ghio D,Brigida I,Greco R,Lupo Stanghellini MT,Peccatori J,Fracchia S,Del Fiacco M,Traversari C,Aiuti A,Del Maschio A,Bordignon C,Ciceri F,Bonini C.T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation.Blood 2012;120:1820-1830[PMID:22709689 DOI:10.1182/blood-2012-01-405670]
106 Ciceri F,Bonini C,Stanghellini MT,Bondanza A,Traversari C,Salomoni M,Turchetto L,Colombi S,Bernardi M,Peccatori J,Pescarollo A,Servida P,Magnani Z,Perna SK,Valtolina V,Crippa F,Callegaro L,Spoldi E,Crocchiolo R,Fleischhauer K,Ponzoni M,Vago L,Rossini S,Santoro A,Todisco E,Apperley J,Olavarria E,Slavin S,Weissinger EM,Ganser A,Stadler M,Yannaki E,Fassas A,Anagnostopoulos A,Bregni M,Stampino CG,Bruzzi P,Bordignon C.Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia(the TK007 trial):a non-randomised phase I-II study.Lancet Oncol 2009;10:489-500[PMID:19345145 DOI:10 .1016/S1470-2045(09)70074-9]
107 Di Stasi A,Tey SK,Dotti G,Fujita Y,Kennedy-Nasser A,Martinez C,Straathof K,Liu E,Durett AG,Grilley B,Liu H,Cruz CR,Savoldo B,Gee AP,Schindler J,Krance RA,Heslop HE,Spencer DM,Rooney CM,Brenner MK.Inducible apoptosis as a safety switch for adoptive cell therapy.N EnglJ Med 2011;365:1673-1683[PMID:22047558 DOI:10.1056/NEJMoa1106152]
108 Bastien JP,Roy J,Roy DC.Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation.Semin Oncol 2012;39:674-682[PMID:23206844 DOI:10.1053/j.seminoncol.2012.09.004]
109 Guinan EC,Boussiotis VA,Neuberg D,Brennan LL,Hirano N,Nadler LM,Gribben JG.Transplantation of anergic histoincompatible bone marrow allografts.N Engl J Med 1999;340:1704-1714[PMID:10352162 DOI:10.1056/NEJM199906033402202]
110 Handgretinger R.New approaches to graft engineering for haploidentical bone marrow transplantation.Semin Oncol 2012;39:664-673[PMID:23206843 DOI:10.1053/j.semino ncol.2012.09.007]
111 Grosso D,Flomenberg N.A two-step approach to allogeneic haploidentical hematopoietic stem cell transplantation.Semin Oncol 2012;39:694-706[PMID:23206846 DOI:10.1053/j.seminoncol.2012.09.006]
112 Grosso D,Carabasi M,Filicko-O’Hara J,Kasner M,Wagner JL,Colombe B,Cornett Farley P,O’Hara W,Flomenberg P,Werner-Wasik M,Brunner J,Mookerjee B,Hyslop T,Weiss M,Flomenberg N.A 2-step approach to myeloablative haploidentical stem cell transplantation:a phase 1/2 trial performed with optimized T-cell dosing.Blood 2011;118:4732-4739[PMID:21868572 DOI:10.1182/blood-2011-07-365338]
113 Brunstein CG,Fuchs EJ,Carter SL,Karanes C,Costa LJ,Wu J,Devine SM,Wingard JR,Aljitawi OS,Cutler CS,Jagasia MH,Ballen KK,Eapen M,O’Donnell PV.Alternative donor transplantation after reduced intensity conditioning:results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.Blood 2011;118:282-288[PMID:21527516 DOI:10 .1182/blood-2011-03-344853]
2 Krbling M,Freireich EJ.Twenty-five years of peripheral blood stem cell transplantation.Blood 2011;117:6411-6416[PMID:21460243 DOI:10.1182/blood-2010-12-322214]
3 Richman CM,Weiner RS,Yankee RA.Increase in circulating stem cells following chemotherapy in man.Blood 1976;47:1031-1039[PMID:1276467]
4 Socinski MA,Cannistra SA,Elias A,Antman KH,Schnipper L,Griffin JD.Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man.Lancet 1988;1:1194-1198[PMID:2897009 DOI:10.1016/S0140-6736(88)92012-0]
5 Dührsen U,Villeval JL,Boyd J,Kannourakis G,Morstyn G,Metcalf D.Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients.Blood 1988;72:2074-2081[PMID:3264199]
6 Prindull G,Prindull B,Meulen N.Haematopoietic stem cells(CFUc)in human cord blood.Acta Paediatr Scand 1978;67:413 -416[PMID:676726 DOI:10.1111/j.1651-2227.1978.tb16347.x]
7 Gluckman E,Broxmeyer HA,Auerbach AD,Friedman HS,Douglas GW,Devergie A,Esperou H,Thierry D,Socie G,Lehn P.Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling.N Engl J Med 1989;321:1174-1178[PMID:2571931 DOI:10.1056/NEJM198910263211707]
8 Switzer GE,Bruce JG,Harrington D,Haagenson M,Drex-ler R,Foley A,Confer D,Bishop M,Anderlini P,Rowley S,Leitman SF,Anasetti C,Wingard JR.Health-related quality of life of bone marrow versus peripheral bood stem cell donors:a prespecified subgroup analysis from a phase III RCTBMTCTN protocol 0201.Biol Blood Marrow Transplant 2013Nov 1;Epub ahead of print[PMID:24184336 DOI:10.1016/j.bbmt.2013.10.024]
9 Powles R,Mehta J,Kulkarni S,Treleaven J,Millar B,Marsden J,Shepherd V,Rowland A,Sirohi B,Tait D,Horton C,Long S,Singhal S.Allogeneic blood and bone-marrow stemcell transplantation in haematological malignant diseases:a randomised trial.Lancet 2000;355:1231-1237[PMID:10770306 DOI:10.1016/S0140-6736(00)02090-0]
10 Blaise D,Kuentz M,Fortanier C,Bourhis JH,Milpied N,Sutton L,Jouet JP,Attal M,Bordigoni P,Cahn JY,Boiron JM,Schuller MP,Moatti JP,Michallet M.Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia:a report from the SociétéFranaise de Greffe de Moelle.J Clin Oncol 2000;18:537-546[PMID:10653869]
11 Couban S,Simpson DR,Barnett MJ,Bredeson C,Hubesch L,Howson-Jan K,Shore TB,Walker IR,Browett P,Messner HA,Panzarella T,Lipton JH.A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies.Blood 2002;100:1525-1531[PMID:12176866DOI:10.1182/blood-2002-01-0048]
12 Bensinger WI,Martin PJ,Storer B,Clift R,Forman SJ,Negrin R,Kashyap A,Flowers ME,Lilleby K,Chauncey TR,Storb R,Appelbaum FR.Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.N Engl J Med 2001;344:175-181[PMID:11172139 DOI:10.1056/NEJM200101183440303]
13 Mielcarek M,Storer B,Martin PJ,Forman SJ,Negrin RS,Flowers ME,Inamoto Y,Chauncey TR,Storb R,Appelbaum FR,Bensinger WI.Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow.Blood 2012;119:2675-2678[PMID:22308289 DOI:10 .1182/blood-2011-12-396275]
14 Oehler VG,Radich JP,Storer B,Blume KG,Chauncey T,Clift R,Snyder DS,Forman SJ,Flowers ME,Martin P,Guthrie KA,Negrin RS,Appelbaum FR,Bensinger W.Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia.Biol Blood Marrow Transplant 2005;11:85 -92[PMID:15682068 DOI:10.1016/j.bbmt.2004.09.010]
15 Schmitz N,Bacigalupo A,Hasenclever D,Nagler A,Gluckman E,Clark P,Bourquelot P,Greinix H,Frickhofen N,Ringdén O,Zander A,Apperley JF,Gorin C,Borkett K,Schwab G,Goebel M,Russell NH,Gratwohl A.Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia:first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation.Bone Marrow Transplant 1998;21:995-1003[PMID:9632272]
16 Schmitz N,Beksac M,Hasenclever D,Bacigalupo A,Ruutu T,Nagler A,Gluckman E,Russell N,Apperley JF,Gorin NC,Szer J,Bradstock K,Buzyn A,Clark P,Borkett K,Gratwohl A.Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemi a.Blood 2002;100:761-767[PMID:12130483 DOI:10.1182/blood-2001-12-0304]
17 Schmitz N,Beksac M,Bacigalupo A,Ruutu T,Nagler A,Gluckman E,Russell N,Apperley J,Szerm J,Bradstock K,Buzyn A,Schlegelberger B,Matcham J,Gratwohl A.Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia:3-year results from the EBMT randomized trial.Haematologica 2005;90:643 -648[PMID:15921379]
18 Friedrichs B,Tichelli A,Bacigalupo A,Russell NH,Ruutu T,Shapira MY,Beksac M,Hasenclever D,SociéG,Schmitz N.Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow:a randomised trial.Lancet Oncol 2010;11:331-338[PMID:20117965 DOI:10 .1016/S1470-2045(09)70352-3]
19 Mohty M,Kuentz M,Michallet M,Bourhis JH,Milpied N,Sutton L,Jouet JP,Attal M,Bordigoni P,Cahn JY,Boiron JM,Blaise D.Chronic graft-versus-host disease after allogeneic blood stem cell transplantation:long-term results of a randomized study.Blood 2002;100:3128-3134[PMID:12384409DOI:10.1182/blood.V100.9.3128]
20 Flowers ME,Parker PM,Johnston LJ,Matos AV,Storer B,Bensinger WI,Storb R,Appelbaum FR,Forman SJ,Blume KG,Martin PJ.Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients:long-term followup of a randomized trial.Blood 2002;100:415-419[PMID:12091330 DOI:10.1182/blood-2002-01-0011]
21 Mahmoud H,Fahmy O,Kamel A,Kamel M,El-Haddad A,El-Kadi D.Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation.Bone Marrow Transplant 1999;24:355-358[PMID:10467322 DOI:10 .1038/sj.bmt.1701906]
22 Morton J,Hutchins C,Durrant S.Granulocyte-colonystimulating factor(G-CSF)-primed allogeneic bone marrow:significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells.Blood 2001;98:3186-3191[PMID:11719353]
23 Vigorito AC,Azevedo WM,Marques JF,Azevedo AM,Eid KA,Aranha FJ,Lorand-Metze I,Oliveira GB,Correa ME,Reis AR,Miranda EC,de Souza CA.A randomised,prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies.Bone Marrow Transplant 1998;22:1145-1151[PMID:9894716 DOI:10.1038/sj.bmt.1701510]
24 Cutler C,Giri S,Jeyapalan S,Paniagua D,Viswanathan A,Antin JH.Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation:a meta-analysis.J Clin Oncol 2001;19:3685-3691[PMID:11504750]
25 Heldal D,Tjnnfjord G,Brinch L,Albrechtsen D,Egeland T,Steen R,Solheim BG,Evensen SA.A randomised study of allogeneic transplantation with stem cells from blood or bone marrow.Bone Marrow Transplant 2000;25:1129-1136[PMID:10849524 DOI:10.1038/sj.bmt.1702422]
26 Horan JT,Liesveld JL,Fernandez ID,Lyman GH,Phillips GL,Lerner NB,Fisher SG.Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies:metaanalysis of randomized controlled trials.Bone Marrow Transplant 2003;32:293-298[PMID:12858201 DOI:10.1038/sj.bmt.1704112]
27 Stem Cell Trialists'Collaborative Group.Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies:an individual patient data meta-analysis of nine randomized trials.J Clin Oncol 2005;23:5074-5087[PMID:16051954 DOI:10 .1200/JCO.2005.09.020]
28 Pidala J,Anasetti C,Kharfan-Dabaja MA,Cutler C,Sheldon A,Djulbegovic B.Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation.Biol Blood Marrow Transplant 2009;15:1415-1421[PMID:19822301 DOI:10.1016/j.bbmt.2009.07.009]
29 Vigorito AC,Marques Júnior JF,Aranha FJ,Oliveira GB,Miranda EC,De Souza CA.A randomized,prospective comparison of allogeneic bone marrow and peripheralblood progenitor cell transplantation in the treatment of hematologic malignancies:an update.Haematologica 2001;86:665 -666[PMID:11418381]
30 Cornelissen JJ,van der Holt B,Petersen EJ,Vindelov L,Russel CA,Hglund M,Maertens J,Schouten HC,Braakman E,Steijaert MM,Zijlmans MJ,Slaper-Cortenbach I,Boogaerts MA,Lwenberg B,Verdonck LF.A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies.Exp Hematol 2003;31:855-864[PMID:14550800 DOI:10.1016/S0301-472 X(03)00195-4]
31 Chang YJ,Weng CL,Sun LX,Zhao YT.Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies:a meta-analysis based on time-to-event data from randomized controlled trials.Ann Hematol 2012;91:427-437[PMID:21789620 DOI:10.1007/s00277-011-1299-8]
32 Anasetti C,Logan BR,Lee SJ,Waller EK,Weisdorf DJ,Wingard JR,Cutler CS,Westervelt P,Woolfrey A,Couban S,Ehninger G,Johnston L,Maziarz RT,Pulsipher MA,Porter DL,Mineishi S,Mc Carty JM,Khan SP,Anderlini P,Bensinger WI,Leitman SF,Rowley SD,Bredeson C,Carter SL,Horowitz MM,Confer DL.Peripheral-blood stem cells versus bone marrow from unrelated donors.N Engl J Med 2012;367:1487-1496[PMID:23075175 DOI:10.1056/NEJMoa1203517]
33 Meisel R,Klingebiel T,Dilloo D.Peripheral blood stem cells versus bone marrow in pediatric unrelated donor stem cell transplantation.Blood 2013;121:863-865[PMID:23372155DOI:10.1182/blood-2012-12-469668]
34 Wang J,Zhan P,Ouyang J,Chen B,Zhou R,Yang Y.Unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients:A meta-analysis.Leuk Res 2010;34:1018-1022[PMID:20031212 DOI:10.1016/j.leukres.2009.11.020]
35 Rocha V,Cornish J,Sievers EL,Filipovich A,Locatelli F,Peters C,Remberger M,Michel G,Arcese W,Dallorso S,Tiedemann K,Busca A,Chan KW,Kato S,Ortega J,Vowels M,Zander A,Souillet G,Oakill A,Woolfrey A,Pay AL,Green A,Garnier F,Ionescu I,Wernet P,Sirchia G,Rubinstein P,Chevret S,Gluckman E.Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia.Blood 2001;97:2962-2971[PMID:11342418]
36 Barker JN,Davies SM,DeF or T,Ramsay NK,Weisdorf DJ,Wagner JE.Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow:results of a matched-pair analysis.Blood 2001;97:2957-2961[PMID:11342417]
37 Dalle JH,Duval M,Moghrabi A,Wagner E,Vachon MF,Barrette S,Bernstein M,Champagne J,David M,Demers J,Rousseau P,Winikoff R,Champagne MA.Results of an unrelated transplant search strategy using partially HLAmismatched cord blood as an immediate alternative to HLAmatched bone marrow.Bone Marrow Transplant 2004;33:605 -611[PMID:14743192 DOI:10.1038/sj.bmt.1704433]
38 Jacobsohn DA,Hewlett B,Ranalli M,Seshadri R,Duerst R,Kletzel M.Outcomes of unrelated cord blood transplants and allogeneic-related hematopoietic stem cell transplants in children with high-risk acute lymphocytic leukemia.Bone Marrow Transplant 2004;34:901-907[PMID:15361908 DOI:10 .1038/sj.bmt.1704681]
39 Laughlin MJ,Eapen M,Rubinstein P,Wagner JE,Zhang MJ,Champlin RE,Stevens C,Barker JN,Gale RP,Lazarus HM,Marks DI,van Rood JJ,Scaradavou A,Horowitz MM.Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia.N Engl J Med 2004;351:2265-2275[PMID:15564543 DOI:10.1056/NEJMoa041276]
40 Rocha V,Labopin M,Sanz G,Arcese W,Schwerdtfeger R,Bosi A,Jacobsen N,Ruutu T,de Lima M,Finke J,Frassoni F,Gluckman E.Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.N Engl J Med 2004;351:2276-2285[PMID:15564544DOI:10.1056/NEJMoa041469]
41 Takahashi S,Iseki T,Ooi J,Tomonari A,Takasugi K,Shimohakamada Y,Yamada T,Uchimaru K,Tojo A,Shirafuji N,Kodo H,Tani K,Takahashi T,Yamaguchi T,Asano S.Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies.Bloo d 2004;104:3813-3820[PMID:15280199 DOI:10.1182/blood-2004-03-1001]
42 Barker JN,Hough RE,van Burik JA,De For TE,MacM illan ML,O’Brien MR,Wagner JE.Serious infections after unrelated donor transplantation in 136 children:impact of stem cell source.Biol Blood Marrow Transplant 2005;11:362-370[PMID:15846290 DOI:10.1016/j.bbmt.2005.02.004]
43 Eapen M,Rubinstein P,Zhang MJ,Stevens C,Kurtzberg J,Scaradavou A,Loberiza FR,Champlin RE,Klein JP,Horowitz MM,Wagner JE.Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia:a comparison study.Lancet 2007;369:1947-1954[PMID:17560447 DOI:10.1016/S0140-6736(07)60915-5]
44 Atsuta Y,Suzuki R,Nagamura-Inoue T,Taniguchi S,Takahashi S,Kai S,Sakamaki H,Kouzai Y,Kasai M,Fukuda T,Azuma H,Takanashi M,Okamoto S,Tsuchida M,Kawa K,Morishima Y,Kodera Y,Kato S.Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia.Blood 2009;113:1631-1638[PMID:19104080DOI:10.1182/blood-2008-03-147041]
45 Eapen M,Rocha V,Sanz G,Scaradavou A,Zhang MJ,Arcese W,Sirvent A,Champlin RE,Chao N,Gee AP,Isola L,Laughlin MJ,Marks DI,Nabhan S,Ruggeri A,Soiffer R,Horowitz MM,Gluckman E,Wagner JE.Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia:a retrospective analysis.Lancet Oncol 2010;11:653-660[PMID:20558104DOI:10.1016/S1470-2045(10)70127-3]
46 Marks DI,Woo KA,Zhong X,Appelbaum FR,Bachanova V,Barker JN,Brunstein CG,Gibson J,Kebriaei P,Lazarus HM,Olsson R,Perales MA,Pidala J,Savani B,Rocha V,Eapen M.Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission:a comparison with allografts from adult unrelated donors.Haematologica 2013 Sep 20;Epub ahead of print[PMID:24056817 DOI:10.3324/haematol.2013.094193]
47 Mac Millan ML,Weisdorf DJ,Brunstein CG,Cao Q,De For TE,Verneris MR,Blazar BR,Wagner JE.Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation:analysis of risk factors.Bl ood 2009;113:2410-2415[PMID:18997171 DOI:10.1182/blood-2008-07-163238]
48 Brunstein CG,Barker JN,Weisdorf DJ,DeF or TE,Miller JS,Blazar BR,Mc Glave PB,Wagner JE.Umbilical cord blood transplantation after nonmyeloablative conditioning:impact on transplantation outcomes in 110 adults with hematologic disease.Blood 2007;110:3064-3070[PMID:17569820 DOI:10 .1182/blood-2007-04-067215]
49 Verneris MR,Brunstein CG,Barker J,MacM illan ML,DeF or T,Mc Kenna DH,Burke MJ,Blazar BR,Miller JS,Mc Glave PB,Weisdorf DJ,Wagner JE.Relapse risk after umbilical cord blood transplantation:enhanced graft-versus-leukemia effect in recipients of 2 units.Blood 2009;114:4293-4299[PMID:19706886 DOI:10.1182/blood-2009-05-220525]
50 Sideri A,Neokleous N,Brunet De La Grange P,Guerton B,Le Bousse Kerdilles MC,Uzan G,Peste-Tsilimidos C,Gluckman E.An overview of the progress on double umbilical cord blood transplantation.Haematologica 2011;96:1213-1220[PMID:21546497 DOI:10.3324/haematol.2010.038836]
51 Sanz J,Wagner JE,Sanz MA,Defor T,Montesinos P,Bachanova V,Lorenzo I,Warlick E,Sanz GF,Brunstein C.Myeloablative cord blood transplantation in adults with acute leukemia:comparison of two different transplant platforms.Biol Blood Marrow Transplant 2013;19:1725-1730[PMID:24090598 DOI:10.1016/j.bbmt.2013.09.015]
52 Ruggeri A,Sanz G,Bittencourt H,Sanz J,Rambaldi A,Volt F,Yakoub-Agha I,Ribera JM,Mannone L,Sierra J,Mohty M,Solano C,Nabhan S,Arcese W,Gluckman E,Labopin M,Rocha V.Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen,a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT.Leukemia 2013 Sep 5;Epub ahead of print[PMID:24005245 DOI:10.1038/leu.2013.259]
53 Kindwall-Keller TL,Hegerfeldt Y,Meyerson HJ,Margevicius S,Fu P,van Heeckeren W,Lazarus HM,Cooper BW,Gerson SL,Barr P,Tse WW,Curtis C,Fanning LR,Creger RJ,Carlson-Barko JM,Laughlin MJ.Prospective study of onevs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies.Bone Marrow Transplant 2012;47:924-933[PMID:22002488 DOI:10.1038/bmt.2011.195]
54 Rodrigues CA,Sanz G,Brunstein CG,Sanz J,Wagner JE,Renaud M,de Lima M,Cairo MS,Fürst S,Rio B,Dalley C,Carreras E,Harousseau JL,Mohty M,Taveira D,Dreger P,Sureda A,Gluckman E,Rocha V.Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies:a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation.J Clin Oncol 2009;27:256-263[PMID:19064984 DOI:10.1200/JCO.2007.15.8865]
55 Avery S,Barker JN.Cord blood transplants:one,two or more unitsCurr Opin Hematol 2010;17:531-537[PMID:20739881 DOI:10.1097/MOH.0b013e32833e5b59]
56 Scaradavou A,Brunstein CG,Eapen M,Le-Rademacher J,Barker JN,Chao N,Cutler C,Delaney C,Kan F,Isola L,Karanes C,Laughlin MJ,Wagner JE,Shpall EJ.Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia.Blood 2013;121:752-758[PMID:23223509 DOI:10.1182/blood-2012-08-449108]
57 Goldstein G,Elhasid R,Bielorai B,Shimoni A,Yerushalmi R,Kassis I,Nagler A.Adults requiring cord blood transplants but have insufficient cell doses from a single cord blood unit can receive two units with successful engraftment kinetics similar to those of children receiving a single unit.Leuk Lymphoma 2011;52:635-641[PMID:21338286 DOI:10.3109/10428194.2010.548109]
58 Yoo KH,Lee SH,Sung KW,Koo HH,Chung NG,Cho B,Kim HK,Kang HJ,Shin HY,Ahn HS,Baek HJ,Han DK,Kook H,Hwang TJ,Kim SY,Lee YH,Hah JO,Im HJ,Seo JJ,Park SK,Jung HJ,Park JE,Lim YJ,Park SS,Lim YT,Yoo ES,Ryu KH,Park HJ,Park BK.Current status of pediatric umbilical cord blood transplantation in Korea:a multicenter retrospective analysis of 236 cases.Am J Hematol 2011;86:12 -17[PMID:21064135 DOI:10.1002/ajh.21886]
59 Robin M,Sanz GF,Ionescu I,Rio B,Sirvent A,Renaud M,Carreras E,Milpied N,Mohty M,Beguin Y,Bordigoni P,de Witte T,Picardi A,Purtill D,Gluckman E,Kroger N,Rocha V.Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia:a survey on behalf of Eurocord and CLWP of EBMT.Leukemia 2011;25:75-81[PMID:20882048 DOI:10.1038/leu.2010.219]
60 Labopin M,Ruggeri A,Gorin NC,Gluckman E,Blaise D,Mannone L,Milpied N,Yakoub-Agha I,Deconinck E,Michallet M,Fegueux N,SociéG,Nguyen S,Cahn JY,de Revel T,Garnier F,Faucher C,Taright N,Kenzey C,Volt F,Bertrand D,Mohty M,Rocha V.Cost-effectiveness and clinical outcomes of double versus single cord bloodtransplantation in adults with acute leukemia in France.Haematologica 2013Oct 18;Epub ahead of print[PMID:24143000 DOI:10.3324/haematol.2013.092254]
61 Rocha V,Labopin M,Ruggeri A,PodestàM,Gallamini A,Bonifazi F,Sanchez-Guijo FM,Rovira M,Socie G,Baltadakis I,Michallet M,Deconinck E,Bacigalupo A,Mohty M,Gluckman E,Frassoni F.Unrelated cord blood transplantation:outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies.Transplantation 2013;95:1284-1291[PMID:23507699 DOI:10.1097/TP.0b013e318288ca4d]
62 Brunstein CG,Gutman JA,Weisdorf DJ,Woolfrey AE,Defor TE,Gooley TA,Verneris MR,Appelbaum FR,Wagner JE,Delaney C.Allogeneic hematopoietic cell transplantation for hematologic malignancy:relative risks and benefits of double umbilical cord blood.Blood 2010;116:4693-4699[PMID:20686119 DOI:10.1182/blood-2010-05-285304]
63 Ponce DM,Zheng J,Gonzales AM,Lubin M,Heller G,Castro-Malaspina H,Giralt S,Hsu K,Jakubowski AA,Jenq RR,Koehne G,Papadopoulos EB,Perales MA,van den Brink MR,Young JW,Boulad F,Kernan NA,Kobos R,Prockop S,Scaradavou A,Small T,O’Reilly RJ,Barker JN.Reduced late mortality risk contributes to similar survival after doubleunit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation.Biol Blood Marrow Transplant 2011;17:1316-1326[PMID:21232625DOI:10.1016/j.bbmt.2011.01.006]
64 Malard F,Fürst S,Loirat M,Chevallier P,El-Cheikh J,Guillaume T,Delaunay J,Le Gouill S,Moreau P,Blaise D,Mohty M.Effect of graft source on mismatched unrelated donor hemopoietic stem cell transplantation after reduced intensity conditioning.Leukemia 2013;27:2113-2117[PMID:23752174DOI:10.1038/leu.2013.170]
65 Le Bourgeois A,Mohr C,Guillaume T,Delaunay J,Malard F,Loirat M,Peterlin P,Blin N,Dubruille V,Mahe B,Gastinne T,Le Gouill S,Moreau P,Mohty M,Planche L,Lode L,Bene MC,Chevallier P.Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases:a single-center analysis.Biol Blood Marrow Transplant 2013;19:934-939[PMID:23523970 DOI:10.1016/j.bbmt.2013.03.009]
66 Chen YB,Aldridge J,Kim HT,Ballen KK,Cutler C,Kao G,Liney D,Bourdeau G,Alyea EP,Armand P,Koreth J,Ritz J,Spitzer TR,Soiffer RJ,Antin JH,Ho VT.Reduced-intensity conditioning stem cell transplantation:comparison of double umbilical cord blood and unrelated donor grafts.Biol Blood Marrow Transplant 2012;18:805-812[PMID:22015993 DOI:10 .1016/j.bbmt.2011.10.016]
67 Jacobson CA,Turki AT,Mc Donough SM,Stevenson KE,Kim HT,Kao G,Herrera MI,Reynolds CG,Alyea EP,Ho VT,Koreth J,Armand P,Chen YB,Ballen K,Soiffer RJ,Antin JH,Cutler CS,Ritz J.Immune reconstitution after double umbilical cord blood stem cell transplantation:comparison with unrelated peripheral blood stem cell transplantation.Biol Blood Marrow Transplant 2012;18:565-574[PMID:21875503DOI:10.1016/j.bbmt.2011.08.018]
68 Di Bartolomeo P,Santarone S,De Angelis G,Picardi A,Cudillo L,Cerretti R,Adorno G,Angelini S,Andreani M,De Felice L,Rapanotti MC,Sarmati L,Bavaro P,Papalinetti G,Di Nicola M,Papola F,Montanari M,Nagler A,Arcese W.Haploidentical,unmanipulated,G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies.Blood 2013;121:849-857[PMID:23165479 DOI:10 .1182/blood-2012-08-453399]
69 Aversa F,Terenzi A,Tabilio A,Falzetti F,Carotti A,Ballanti S,Felicini R,Falcinelli F,Velardi A,Ruggeri L,Aloisi T,Saab JP,Santucci A,Perruccio K,Martelli MP,Mecucci C,Reisner Y,Martelli MF.Full haplotype-mismatched hematopoietic stem-cell transplantation:a phase II study in patients with acute leukemia at high risk of relapse.J Clin Oncol 2005;23:3447-3454[PMID:15753458 DOI:10.1200/JCO.2005.09.117]
70 Ciurea SO,Saliba R,Rondon G,Pesoa S,Cano P,FernandezVina M,Qureshi S,Worth LL,Mc Mannis J,Kebriaei P,Jones RB,Korbling M,Qazilbash M,Shpall EJ,Giralt S,de Lima M,Champlin RE,Gajewski J.Reduced-intensity conditioning using fludarabine,melphalan and thiotepa for adult patients undergoing haploidentical SCT.Bone Marrow Transplant 2010;45:429-436[PMID:19668237 DOI:10.1038/bmt.2009.189]
71 Aversa F,Terenzi A,Felicini R,Tabilio A,Falzetti F,Carotti A,Falcinelli F,Sodani P,Amici A,Zucchetti P,Mazzarino I,Martelli MF.Mismatched T cell-depleted hematopoietic stem cell transplantation for children with high-risk acute leukemia.Bone Marrow Transplant 1998;22 Suppl 5:S29-S32[PMID:9989886]
72 Handgretinger R,Klingebiel T,Lang P,Schumm M,Neu S,Geiselhart A,Bader P,Schlegel PG,Greil J,Stachel D,Herzog RJ,Niethammer D.Megadose transplantation of purified peripheral blood CD34(+)progenitor cells from HLA-mismatched parental donors in children.Bone Marrow Transplant 2001;27:777-783[PMID:11477433 DOI:10.1038/sj.bmt.1702996]
73 Peters C,Matthes-Martin S,Fritsch G,Holter W,Lion T,Witt V,Hcker P,Fischer G,Dieckmann K,Handgretinger R,Klingebiel T,Gadner H.Transplantation of highly purified peripheral blood CD34+cells from HLA-mismatched parental donors in 14 children:evaluation of early monitoring of engraftment.Leukemia 1999;13:2070-2078[PMID:10602431]
74 Ortín M,Raj R,Kinning E,Williams M,Darbyshire PJ.Partially matched related donor peripheral blood progenitor cell transplantation in paediatric patients adding fludarabine and anti-lymphocyte gamma-globulin.Bone Marrow Transplant 2002;30:359-366[PMID:12235520 DOI:10.1038/sj.bmt.1703667]
75 Lang P,Greil J,Bader P,Handgretinger R,Klingebiel T,Schumm M,Schlegel PG,Feuchtinger T,Pfeiffer M,ScheelWalter H,Führer M,Martin D,Niethammer D.Long-term outcome after haploidentical stem cell transplantation in children.Blood Cells Mol Dis 2004;33:281-287[PMID:15528145 DOI:10.1016/j.bcmd.2004.08.017]
76 Klingebiel T,Handgretinger R,Lang P,Bader P,Niethammer D.Haploidentical transplantation for acute lymphoblastic leukemia in childhood.Blood Rev 2004;18:181-192[PMID:15183902 DOI:10.1016/S0268-960X(03)00063-8]
77 Marks DI,Khattry N,Cummins M,Goulden N,Green A,Harvey J,Hunt LP,Keen L,Robinson SP,Steward CG,Cornish JM.Haploidentical stem cell transplantation for children with acute leukaemia.Br J Haematol 2006;134:196-201[PMID:16846478 DOI:10.1111/j.1365-2141.2006.06140.x]
78 Reisner Y,Martelli MF.Tolerance induction by‘megadose’transplants of CD34+stem cells:a new option for leukemia patients without an HLA-matched donor.Curr Opin Immunol 2000;12:536-541[PMID:11007356]
79 Klingebiel T,Cornish J,Labopin M,Locatelli F,Darbyshire P,Handgretinger R,Balduzzi A,Owoc-Lempach J,Fagioli F,Or R,Peters C,Aversa F,Polge E,Dini G,Rocha V.Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia:impact of center size:an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group.Blood 2010;115:3437-3446[PMID:20040760 DOI:10.1182/blood-2009-03-207001]
80 Symons HJ,Leffell MS,Rossiter ND,Zahurak M,Jones RJ,Fuchs EJ.Improved survival with inhibitory killer immunoglobulin receptor(KIR)gene mismatches and KIR haplotype B donors after nonmyeloablative,HLA-haploidentical bone marrow transplantation.Biol Blood Marrow Transplant 2010;16:533-542[PMID:19961944 DOI:10.1016/j.bbmt.2009.11.022]
81 Lang P,Schumm M,Greil J,Bader P,Klingebiel T,Müller I,Feuchtinger T,Pfeiffer M,Schlegel PG,Niethammer D,Handgretinger R.A comparison between three graft manipulation methods for haploidentical stem cell transplantation in pediatric patients:preliminary results of a pilot study.Klin Padiatr 2005;217:334-338[PMID:16307419 DOI:10.1055/s-2005-872529]
82 Federmann B,Bornhauser M,Meisner C,Kordelas L,Beelen DW,Stuhler G,Stelljes M,Schwerdtfeger R,Christopeit M,Behre G,Faul C,Vogel W,Schumm M,Handgretinger R,Kanz L,Bethge WA.Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning:a phase II study.Haematologica 2012;97:1523-1531[PMID:22491731 DOI:10.3324/haematol.2011.059378]
83 Palma J,Salas L,Carrión F,Sotomayor C,Catalán P,Paris C,Turner V,Jorquera H,Handgretinger R,Rivera GK.Haploidentical stem cell transplantation for children with highrisk leukemia.Pediatr Blood Cancer 2012;59:895-901[PMID:22238059 DOI:10.1002/pbc.24022]
84 Chen DF,Prasad VK,Broadwater G,Reinsmoen NL,DeOliveira A,Clark A,Sullivan KM,Chute JP,Horwitz ME,Gasparetto C,Long GD,Yang Y,Chao NJ,Rizzieri DA.Differential impact of inhibitory and activating Killer Ig-Like Receptors(KIR)on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors.Bone Marrow Transplant 2012;47:817-823[PMID:22139069 DOI:10.1038/bmt.2011.181]
85 Handgretinger R,Chen X,Pfeiffer M,Mueller I,Feuchtinger T,Hale GA,Lang P.Feasibility and outcome of reducedintensity conditioning in haploidentical transplantation.Ann N Y Acad Sci 2007;1106:279-289[PMID:17442774 DOI:10 .1196/annals.1392.022]
86 Chen X,Hale GA,Barfield R,Benaim E,Leung WH,Knowles J,Horwitz EM,Woodard P,Kasow K,Yusuf U,Behm FG,Hayden RT,Shurtleff SA,Turner V,Srivastava DK,Handgretinger R.Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies.Br J Haematol 2006;135:524-532[PMID:17010105 DOI:10.1111/j.1365-2141.2006.06330.x]
87 Raiola AM,Dominietto A,Ghiso A,Di Grazia C,Lamparelli T,Gualandi F,Bregante S,Van Lint MT,Geroldi S,Luchetti S,Ballerini F,Miglino M,Varaldo R,Bacigalupo A.Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.Biol Blood Marrow Transplant 2013;19:117-122[PMID:22940057 DOI:10 .1016/j.bbmt.2012.08.014]
88 Solomon SR,Sizemore CA,Sanacore M,Zhang X,Brown S,Holland HK,Morris LE,Bashey A.Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival:results of a prospective phase II trial.Biol Blood Marrow Transplant 2012;18:1859-1866[PMID:22863841 DOI:10 .1016/j.bbmt.2012.06.019]
89 Wang HX,Yan HM,Wang ZD,Xue M,Liu J,Guo ZK.Haploidentical hematopoietic stem cell transplantation in hematologic malignancies with G-CSF mobilized bone marrow plus peripheral blood stem cells grafts without T celldepletion:a single center report of 29 cases.Leuk Lymphoma 2012;53:654-659[PMID:21929286 DOI:10.3109/10428194.2011.624225]
90 Munchel AT,Kasamon YL,Fuchs EJ.Treatment of hematological malignancies with nonmyeloablative,HLAhaploidentical bone marrow transplantation and high dose,post-transplantation cyclophosphamide.Best Pract Res Clin Haematol 2011;24:359-368[PMID:21925089 DOI:10.1016/j.beha.2011.05.001]
91 Chen Y,Liu K,Xu L,Chen H,Liu D,Zhang X,Shi H,Han W,Wang Y,Zhao T,Wang J,Wang J,Huang X.HLAmismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome.Bone Marrow Transplant 2010;45:1333-1339[PMID:20062100 DOI:10.1038/bmt.2009.351]
92 Wang HX,Yan HM,Duan LN,Wang ZD,Zhu L,Xue M,Liu J,Hu LD,Guo ZK.Haploidentical hematopoietic stem cell transplantation in child hematologic malignancies with G-CSF-mobilized marrow grafts without T-cell depletion:a single-center report of 45 cases.Pediatr Hematol Oncol 2009;26:119-128[PMID:19382033]
93 Luznik L,O’Donnell PV,Symons HJ,Chen AR,Leffell MS,Zahurak M,Gooley TA,Piantadosi S,Kaup M,Ambinder RF,Huff CA,Matsui W,Bolaos-Meade J,Borrello I,Powell JD,Harrington E,Warnock S,Flowers M,Brodsky RA,Sandmaier BM,Storb RF,Jones RJ,Fuchs EJ.HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose,posttransplantation cyclophosphamide.Biol Blood Marrow Transplant 2008;14:641-650[PMID:18489989 DOI:10.1016/j.bbmt.2008.03.005]
94 Liu D,Huang X,Liu K,Xu L,Chen H,Han W,Chen Y,Zhang X,Jiang Q.Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children.Biol Blood Marrow Transplant 2008;14:469-477[PMID:18342790 DOI:10 .1016/j.bbmt.2008.02.007]
95 Yoshihara T,Okada K,Kobayashi M,Kikuta A,Kato K,Adachi N,Kikuchi A,Ishida H,Hirota Y,Kuroda H,Nagatoshi Y,Inukai T,Koike K,Kigasawa H,Yagasaki H,Tokuda K,Kishimoto T,Nakano T,Fujita N,Goto H,Nakazawa Y,Kanegane H,Matsuzaki A,Osugi Y,Hasegawa D,Uoshima N,Nakamura K,Tsuchida M,Tanaka R,Watanabe A,Yabe H.Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents.Int J Hematol 2007;85:246-255[PMID:17483063 DOI:10.1532/IJH97.06185]
96 Bashey A,Zhang X,Sizemore CA,Manion K,Brown S,Holland HK,Morris LE,Solomon SR.T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.J Clin Oncol 2013;31:1310-1316[PMID:23423745 DOI:10 .1200/JCO.2012.44.3523]
97 Ciurea SO,Mulanovich V,Saliba RM,Bayraktar UD,Jiang Y,Bassett R,Wang SA,Konopleva M,Fernandez-Vina M,Montes N,Bosque D,Chen J,Rondon G,Alatrash G,Alousi A,Bashir Q,Korbling M,Qazilbash M,Parmar S,Shpall E,Nieto Y,Hosing C,Kebriaei P,Khouri I,Popat U,de Lima M,Champlin RE.Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.Biol Blood Marrow Transplant 2012;18:1835-1844[PMID:22796535 DOI:10 .1016/j.bbmt.2012.07.003]
98 Dodero A,Carniti C,Raganato A,Vendramin A,Farina L,Spina F,Carlo-Stella C,Di Terlizzi S,Milanesi M,Longoni P,Gandola L,Lombardo C,Corradini P.Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies:posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery.Blood 2009;113:4771-4779[PMID:19211934 DOI:10.1182/blood-2008-10-183723]
99 Di Ianni M,Falzetti F,Carotti A,Terenzi A,Castellino F,Bonifacio E,Del Papa B,Zei T,Ostini RI,Cecchini D,Aloisi T,Perruccio K,Ruggeri L,Balucani C,Pierini A,Sportoletti P,Aristei C,Falini B,Reisner Y,Velardi A,Aversa F,Martelli MF.Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation.Bl ood 2011;117:3921-3928[PMID:21292771 DOI:10.1182/blood-2010-10-311894]
100 Di Ianni M,Falzetti F,Carotti A,Terenzi A,Del Papa B,Perruccio K,Ruggeri L,Sportoletti P,Rosati E,Marconi P,Falini B,Reisner Y,Velardi A,Aversa F,Martelli MF.Immunoselection and clinical use of T regulatory cells in HLAhaploidentical stem cell transplantation.Best Pract Res Clin Haematol 2011;24:459-466[PMID:21925099 DOI:10.1016/j.beha.2011.05.005]
101 Liu K,Chen Y,Zeng Y,Xu L,Liu D,Chen H,Zhang X,Han W,Wang Y,Zhao T,Wang J,Wang J,Han Q,Zhao C,Huang X.Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation:a randomized,controlled clinical study.Stem Cells Dev 2011;20:1679-1685[PMID:21142788 DOI:10.1089/scd.2010.0447]
102 Ball LM,Bernardo ME,Roelofs H,Lankester A,Cometa A,Egeler RM,Locatelli F,Fibbe WE.Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation.Blood 2007;110:2764-2767[PMID:17638847 DOI:10.1182/blood-2007-04-087056]
103 Xu LP,Liu KY,Liu DH,Chen H,Han W,Chen YH,Wang Y,Huang XJ.The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation:a comparative analysis.Bone Marrow Transplant 2010;45:985-992[PMID:19898505 DOI:10.1038/bmt.2009.311]
104 Yan HM,Xue M,Wang ZD,Zhu L,Liu J,Ding L,Pan SP,Duan LN,Wang HX.[Haploidentical allogeneic bone marrow stem cell transplantation combined with peripheral blood stem cells for therapy of leukemia].Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009;17:1330-1334[PMID:19840477]
105 Vago L,Oliveira G,Bondanza A,Noviello M,Soldati C,Ghio D,Brigida I,Greco R,Lupo Stanghellini MT,Peccatori J,Fracchia S,Del Fiacco M,Traversari C,Aiuti A,Del Maschio A,Bordignon C,Ciceri F,Bonini C.T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation.Blood 2012;120:1820-1830[PMID:22709689 DOI:10.1182/blood-2012-01-405670]
106 Ciceri F,Bonini C,Stanghellini MT,Bondanza A,Traversari C,Salomoni M,Turchetto L,Colombi S,Bernardi M,Peccatori J,Pescarollo A,Servida P,Magnani Z,Perna SK,Valtolina V,Crippa F,Callegaro L,Spoldi E,Crocchiolo R,Fleischhauer K,Ponzoni M,Vago L,Rossini S,Santoro A,Todisco E,Apperley J,Olavarria E,Slavin S,Weissinger EM,Ganser A,Stadler M,Yannaki E,Fassas A,Anagnostopoulos A,Bregni M,Stampino CG,Bruzzi P,Bordignon C.Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia(the TK007 trial):a non-randomised phase I-II study.Lancet Oncol 2009;10:489-500[PMID:19345145 DOI:10 .1016/S1470-2045(09)70074-9]
107 Di Stasi A,Tey SK,Dotti G,Fujita Y,Kennedy-Nasser A,Martinez C,Straathof K,Liu E,Durett AG,Grilley B,Liu H,Cruz CR,Savoldo B,Gee AP,Schindler J,Krance RA,Heslop HE,Spencer DM,Rooney CM,Brenner MK.Inducible apoptosis as a safety switch for adoptive cell therapy.N EnglJ Med 2011;365:1673-1683[PMID:22047558 DOI:10.1056/NEJMoa1106152]
108 Bastien JP,Roy J,Roy DC.Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation.Semin Oncol 2012;39:674-682[PMID:23206844 DOI:10.1053/j.seminoncol.2012.09.004]
109 Guinan EC,Boussiotis VA,Neuberg D,Brennan LL,Hirano N,Nadler LM,Gribben JG.Transplantation of anergic histoincompatible bone marrow allografts.N Engl J Med 1999;340:1704-1714[PMID:10352162 DOI:10.1056/NEJM199906033402202]
110 Handgretinger R.New approaches to graft engineering for haploidentical bone marrow transplantation.Semin Oncol 2012;39:664-673[PMID:23206843 DOI:10.1053/j.semino ncol.2012.09.007]
111 Grosso D,Flomenberg N.A two-step approach to allogeneic haploidentical hematopoietic stem cell transplantation.Semin Oncol 2012;39:694-706[PMID:23206846 DOI:10.1053/j.seminoncol.2012.09.006]
112 Grosso D,Carabasi M,Filicko-O’Hara J,Kasner M,Wagner JL,Colombe B,Cornett Farley P,O’Hara W,Flomenberg P,Werner-Wasik M,Brunner J,Mookerjee B,Hyslop T,Weiss M,Flomenberg N.A 2-step approach to myeloablative haploidentical stem cell transplantation:a phase 1/2 trial performed with optimized T-cell dosing.Blood 2011;118:4732-4739[PMID:21868572 DOI:10.1182/blood-2011-07-365338]
113 Brunstein CG,Fuchs EJ,Carter SL,Karanes C,Costa LJ,Wu J,Devine SM,Wingard JR,Aljitawi OS,Cutler CS,Jagasia MH,Ballen KK,Eapen M,O’Donnell PV.Alternative donor transplantation after reduced intensity conditioning:results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.Blood 2011;118:282-288[PMID:21527516 DOI:10 .1182/blood-2011-03-344853]